Eugenics and the Human/Animal Divide in Guardians of the Galaxy Vol. 3
By Leigha McReynolds,
Tor
| 09. 19. 2023
The 2011 X-Men franchise prequel, X-Men: First Class, briefly featured a mutant named Darwin who could adapt to any circumstances. For example, when he stuck his head in a fish tank he grew gills. Now if you’re a history of science nerd like me, you both appreciate the Darwinian reference and wish that the movie had instead named the character Lamarck, who theorized that individual animals could adapt to environments and experience physical changes during their lives—but that doesn’t have quite the same ring to it. Darwin, on the other hand, believed that species changed through heredity and over many generations.
While in this case the slippage between evolutionary theorists and their ideas is harmless, there is a long tradition of misusing Darwin’s theory of evolution through natural selection to explain and justify concepts that are not scientific but are actually actively harmful. The creation and deployment of the term “social Darwinism” is one, and the development of the pseudoscience of eugenics in the late nineteenth century is another. Eugenics took concepts rooted in Darwin’s evolutionary theory and used...
Related Articles
By Staff, The Economist | 02.21.2025
One of the greatest scandals in modern science began with a late-2010s advertisement for HIV-positive couples looking to have children through in-vitro fertilisation (IVF). The ad had been put out by a scientist named He Jiankui, a biologist then at...
By Matthew Cobb, Nature | 02.17.2025
On 24 February 1975, some 150 people met at the Asilomar Conference Grounds near Monterey on the Californian coast. They were mostly scientists from the United States, together with representatives of various companies and government agencies, and 16 journalists. Their...
By Angus Liu, Fierce Pharma | 02.21.2025
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez.
The New York pharma is ending global development and commercialization of Beqvez less than a year after an FDA approval for the...
By Angelica Peebles, CNBC | 02.21.2025
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird’s fall from the one of the buzziest biotech firms to one that was...